Canaccord Genuity reiterated their buy rating on shares of Aptose Biosciences Inc. (NASDAQ:APTO) in a research report released on Saturday morning. Canaccord Genuity currently has a $7.00 price target on the stock.
Several other research analysts have also weighed in on APTO. Royal Bank Of Canada reissued an outperform rating and issued a $23.00 price objective on shares of Aptose Biosciences in a research report on Saturday, June 25th. Zacks Investment Research lowered Aptose Biosciences from a hold rating to a sell rating in a research report on Monday, July 11th. Finally, RBC Capital Markets reissued an outperform rating on shares of Aptose Biosciences in a research report on Tuesday, September 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.40 on Friday. Aptose Biosciences has a 52-week low of $1.92 and a 52-week high of $6.40. The stock has a 50 day moving average price of $2.22 and a 200-day moving average price of $2.47. The firm’s market capitalization is $30.94 million.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences at the end of the most recent reporting period. 19.47% of the stock is currently owned by institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.